Extended Data Table 1 Baseline characteristics for the analysis-eligible population

From: Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

  1. Data are n (%) except otherwise noted. CPS, combined positive score; ctDNA, circulating tumor DNA; ECOG PS, Easter Cooperative Oncology Group performance status; IQR, interquartile range; maxVAF, maximum variant allele frequency; PD-L1, programmed death ligand 1.
Back to article page